Lifecore Biomedical, Inc.
LFCR • NASDAQ
Lifecore Biomedical, Inc. is a drug manufacturers - specialty & generic company in the healthcare sector trading on NASDAQ, led by CEO Paul Josephs, with a market cap of $283.2M.
CEOPaul Josephs
Market Cap$283.2M
Drug Manufacturers - Specialty & Generic
Healthcare
Employees459.0
Websitelifecore.com
Country
United States of America
Next Earnings
Upcoming earnings announcement for Lifecore Biomedical, Inc.
Date
Thursday, April 2, 2026 (in 2 months)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q3 2026
EPS Estimate
-$0.25
Revenue Estimate
$29.8M
Earnings History
Past 11 earnings reports for Lifecore Biomedical, Inc.
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Nov 6, 2025 | Q1 2026 | -$0.29Est: -$0.30 | +3.3% | $31.1MEst: $26.6M | +17.1% |  10-Q |
| Aug 7, 2025 | Q4 2025 | -$0.06Est: -$0.09 | +33.3% | $36.4MEst: $35.5M | +2.6% | 10-K |
| Apr 3, 2025 | Q3 2025 | -$0.28Est: -$0.15 | -86.7% | $35.2MEst: $33.2M | +5.8% | 10-Q |
| Jan 2, 2025 | Q2 2025 | -$0.25Est: -$0.31 | +19.4% | $32.6MEst: $29.8M | +9.5% | 10-Q |
| Oct 4, 2024 | Q1 2025 | -$0.53Est: -$0.46 | -15.2% | $24.7MEst: $23.2M | +6.5% | 10-Q |
| Aug 26, 2024 | Q4 2024 | -$0.20Est: -$0.26 | +23.1% | $37.9MEst: $24.4M | +55.1% | 10-K |
| Aug 9, 2024 | Q1 2024 | -$0.41Est: -$0.26 | -57.7% | $24.5MEst: $24.4M | +0.4% | 10-Q |
| Aug 31, 2023 | Q4 2023 | -$0.11Est: -$0.37 | +70.3% | $31.5MEst: $29.0M | +8.7% | — |
| Jun 1, 2023 | Q3 2023 | -$0.22Est: -$0.13 | -69.2% | $27.6MEst: $28.0M | -1.4% | — |
| Mar 16, 2023 | Q2 2023 | -$0.24Est: $0.03 | -900.0% | $38.8MEst: $54.5M | -28.9% | — |
| Oct 6, 2022 | Q1 2023 | -$0.32Est: -$0.13 | -146.2% | $43.4MEst: $42.7M | +1.4% | — |